Related Experiment Video
Updated: Apr 20, 2026
09:55
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
1.1K
Dual-radiolabeled nanoparticle SPECT probes for bioimaging
Kvar C L Black1, Walter J Akers, Gail Sudlow
1Department of Radiology, Washington University, St. Louis, Missouri 63110, USA.
Nanoscale
|November 25, 2014
Summary
This study developed a novel multispectral SPECT imaging agent using gold nanoparticles. The agent showed targeted delivery and distinct behavior in tumors based on matrix metalloproteinase-9 (MMP9) expression levels.
Area of Science:
- Nanotechnology
- Radiochemistry
- Molecular Imaging
Background:
- Matrix metalloproteinase-9 (MMP9) is implicated in tumor progression and metastasis.
- Developing targeted imaging agents for cancer diagnostics is crucial.
- Multispectral Single Photon Emission Computed Tomography (SPECT) offers enhanced imaging capabilities.
Purpose of the Study:
- To create and characterize a novel multispectral SPECT imaging contrast agent.
- To evaluate the MMP9-cleavable peptide functionality in vitro.
- To assess the agent's performance in tumors with varying MMP9 expression.
Main Methods:
- Radiolabeling of gold nanoparticles with Iodine-125 ((125)I) and Indium-111 ((111)In).
- Functionalization with a matrix metalloproteinase-9 (MMP9)-cleavable peptide.
- In vitro assessment of peptide cleavage by MMP9.
- In vivo pharmacokinetic studies in tumor models with differential MMP9 expression.
Main Results:
- Successful radiolabeling and functionalization of gold nanoparticles.
- Demonstrated in vitro cleavage of the peptide by MMP9.
- Observed distinct pharmacokinetic profiles of the contrast agent correlating with tumor MMP9 levels.
- Multispectral SPECT imaging potential was established.
Conclusions:
- The developed gold nanoparticle-based agent functions as a multispectral SPECT imaging contrast agent.
- The MMP9-cleavable peptide enables MMP9-specific targeting and detection.
- This agent shows promise for non-invasively assessing MMP9 expression in tumors.
